Trial Information
A randomized phase 3 trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2-) negative early breast cancer
Sponsor: Alliance Foundation Trials (AFT) LLC; ABCSG, GmbH
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
